How does orforglipron compare to other GLP-1 options?

Orforglipron is awaiting FDA approval (PDUFA April 10, 2026). If approved, it would be available at $149/month via LillyDirect — the cheapest brand-name GLP-1. It produces 12.4% weight loss in trials (less than semaglutide's 14.9% or tirzepatide's 20.9%) but offers key advantages: daily oral pill, no fasting requirements, and the lowest brand-name price point. Higher GI side effects (59% nausea) than alternatives. Good for patients who want an affordable, convenient oral option and don't need maximum weight loss.

Patient Guides

GLP-1 Medication Comparison Chart 2026: Every Weight Loss Drug Compared

Updated March 29, 2026

Fact Checked

Master comparison chart of every GLP-1 weight loss medication in 2026 — semaglutide, tirzepatide, orforglipron, retatrutide, and CagriSema compared by efficacy, pricing, side effects, insurance coverage, and availability to help you choose the right option.

Key Takeaways

Wegovy: 14.9% weight loss, $1,349/month list. Zepbound: 20.9%, $299/month via LillyDirect.
Orforglipron (PDUFA April 10, 2026): 12.4% weight loss, $149/month — lowest brand-name price.
Retatrutide: 28.7% weight loss in Phase 2; TRIUMPH-1 Phase 3 is ongoing as of April 2026.
Tirzepatide nausea rate ~31% vs semaglutide ~44% at doses producing equivalent weight loss.
Medicare Bridge program ($50/month cap) is scheduled to launch July 2026.

On this page

Find your match

Answer a few questions and we’ll match you with the right provider and medication.

Take the Quiz →

Free · 2 min · No signup required

GLP-1 Medication Comparison Chart 2026: Every Weight Loss Drug Compared

There are now more GLP-1 weight loss medications available or approaching market than at any point in history. Choosing between them — based on efficacy, cost, route of administration, insurance coverage, and availability — requires comparing dozens of data points across multiple drugs.

This page is our master comparison resource. It covers every FDA-approved GLP-1 medication for weight loss, every significant pipeline drug nearing approval, and the compounded alternatives that many patients use today. We update it as new drugs launch, prices change, or clinical data shifts the picture.

How to use this page: Start with the master comparison chart below for a high-level view. Then use the decision framework to narrow down which medication fits your specific situation — insurance status, budget, preference for pills vs. injections, and how much weight loss you are targeting.

Master Comparison Chart: FDA-Approved Medications

These are the GLP-1-class medications currently approved by the FDA for weight management or type 2 diabetes (with documented weight loss effects).

Drug	Brand	Type	Route	Frequency	Weight Loss	Nausea Rate	Cash Price	Insurance	Available
Semaglutide	Wegovy (injection)	GLP-1	Injection	Weekly	14.9%	44%	$1,349/mo list	Yes	Yes
Semaglutide	Oral Wegovy	GLP-1	Pill	Daily	16.6%	47%	$199-299/mo	Yes	Yes
Semaglutide	Ozempic	GLP-1	Injection	Weekly	~12%	20%	$935/mo list	Yes (diabetes)	Yes
Tirzepatide	Zepbound	GIP/GLP-1	Injection	Weekly	20.9%	31%	$299/mo LillyDirect	Yes	Yes
Tirzepatide	Mounjaro	GIP/GLP-1	Injection	Weekly	20.9%	31%	$1,060/mo list	Yes (diabetes)	Yes
Orforglipron	(Eli Lilly)	GLP-1	Pill	Daily	12.4%	59%	$149/mo LillyDirect	Yes	Yes (new 2026)

Reading this chart:

Weight loss figures are mean percentage body weight loss from pivotal clinical trials at the highest approved dose. Individual results vary significantly — some patients lose more, some less.
Cash price is list price without insurance or manufacturer discounts unless noted. "LillyDirect" indicates Eli Lilly's direct self-pay pricing, which is significantly below list. Actual out-of-pocket costs vary widely based on insurance, savings cards, and pharmacy.
Ozempic is FDA-approved for type 2 diabetes, not weight management. The ~12% weight loss figure reflects its diabetes trial data at the 2 mg dose. Prescribers sometimes use it off-label for weight loss, but insurance typically covers it only for diabetes.
Oral Wegovy was approved in late 2025 and represents the first oral semaglutide formulation specifically indicated for weight management. It requires taking the pill on an empty stomach 30 minutes before food.
Orforglipron is awaiting FDA approval (PDUFA April 10, 2026). It is a small-molecule (non-peptide) GLP-1 agonist — meaning it does not require the fasting/water restrictions of oral semaglutide. At an announced $149/month via LillyDirect, it would be the cheapest brand-name GLP-1 medication available. Its 12.4% weight loss in trials is lower than other options but sufficient for many patients, particularly those prioritizing convenience and cost.
Zepbound pricing updated: LillyDirect offers Zepbound at $299/month self-pay through December 2026, down from $1,060/month list.
Medicare Bridge (expected July 1, 2026): $50/month copay for Wegovy, Zepbound, and orforglipron (pending approval) for eligible Medicare enrollees.

Key Takeaways from the Approved Drug Chart

Tirzepatide (Zepbound/Mounjaro) produces the most weight loss among currently approved medications — 20.9% mean body weight loss in the SURMOUNT trials. It targets both GLP-1 and GIP receptors, which appears to be the source of its advantage over semaglutide alone.

Oral Wegovy slightly outperforms injectable Wegovy on weight loss (16.6% vs. 14.9%), though the oral version has a higher nausea rate (47% vs. 44%) and requires daily dosing with food-timing restrictions. The choice between them often comes down to preference: daily pill vs. weekly injection.

Ozempic is not a weight loss medication by FDA labeling. It is included here because many patients encounter it in their research, and prescribers sometimes use it off-label. If weight loss is your primary goal, Wegovy or Zepbound are the appropriate FDA-approved options.

Pipeline Medications: Not Yet Available

These drugs are in late-stage clinical trials or under FDA review. None are available for prescription today, but several could reach the market within the next 1-3 years.

Drug	Company	Type	Route	Frequency	Weight Loss	Phase	Est. Available
Orforglipron	Eli Lilly	GLP-1	Daily pill	Daily	11.2%	FDA review (PDUFA Apr 10, 2026)	Mid-2026
CagriSema	Novo Nordisk	GLP-1/Amylin	Injection	Weekly	23%	NDA filed Dec 2025	Late 2026
Retatrutide	Eli Lilly	GLP-1/GIP/Glucagon	Injection	Weekly	28.7%	Phase 3	2027-2028
Survodutide	Boehringer Ingelheim	GLP-1/Glucagon	Injection	Weekly	18.7%	Phase 3	2028+
Amycretin (zenagamtide)	Novo Nordisk	GLP-1/Amylin	Both (oral + injectable)	TBD	22%	Phase 3	2028+
Aleniglipron	Structure Therapeutics	GLP-1 (small molecule)	Daily pill	Daily	16.3%	Phase 2 (Phase 3 H2 2026)	2028+

Important caveats about pipeline data:

Weight loss figures for pipeline drugs come from clinical trials of varying size and duration. Phase 2 numbers (survodutide, amycretin, aleniglipron) are preliminary and may not replicate in Phase 3.
Retatrutide's 28.7% figure is from Phase 3 (TRIUMPH-1) and is the most robust pipeline data point.
Orforglipron's 11.2% is confirmed Phase 3 data (ATTAIN-1). Lower than injectables, but the $149/month price and oral convenience are the value proposition.
Estimated availability dates are optimistic projections that assume successful trials and standard FDA review. Delays are common.

For a deep dive into every pipeline drug, see our GLP-1 Drug Pipeline 2026-2027 guide.

Compounded Options

Compounded GLP-1 medications are custom-prepared versions of FDA-approved drugs, made by compounding pharmacies. They are not FDA-approved as finished products but are legal under certain conditions when there is a documented shortage or medical need.

Drug	Route	Frequency	Cash Price	FDA-Approved?
Compounded semaglutide	Injection	Weekly	$99-199/mo	No (as finished product)
Compounded tirzepatide	Injection	Weekly	$249-349/mo	No (as finished product)

What patients need to know about compounded options:

Price is the primary advantage. Compounded semaglutide at $99-199/month is substantially less than brand-name Wegovy at $1,349/month list price.
Quality varies by pharmacy. Compounding pharmacies are regulated by state boards of pharmacy and, in the case of outsourcing facilities, by the FDA under Section 503B. Quality, potency, and sterility standards vary. Choose pharmacies with 503B outsourcing facility status when possible.
The legal landscape is shifting. Compounded versions are permitted when the brand-name drug is on the FDA drug shortage list. As shortages resolve, the availability of compounded options may change. This is an evolving regulatory situation.
They are not bioequivalent. Compounded versions have not undergone the same bioequivalence testing as branded generics. Potency and absorption may differ.
No insurance coverage. Compounded medications are always cash-pay.

Compounded options make the most sense for patients who cannot afford brand-name medications and do not have insurance coverage for GLP-1s. If you have insurance that covers Wegovy or Zepbound, the brand-name version is generally the better choice for quality assurance and clinical consistency.

How to Choose: Decision Framework

There is no single "best" GLP-1 medication. The right choice depends on your insurance status, budget, tolerance for injections, weight loss goals, and how long you are willing to wait. Here is a structured way to think through it.

Step 1: What Can You Access?

Your starting point is not "which drug is best" — it is "which drugs can I actually get?"

Have insurance that covers GLP-1s? Your formulary determines your options. Most plans that cover weight loss medications include either Wegovy or Zepbound (or both). Your copay may be $25-50/month.
Have Medicare? As of 2026, Medicare covers Wegovy and Zepbound for weight management with a $50/month cap under the Inflation Reduction Act provisions.
No insurance coverage? Your options are cash-pay brand (expensive), compounded (moderate cost, under regulatory pressure), or orforglipron ($149/month announced, pending FDA approval).

Step 2: Pills or Injections?

This is a bigger decision than many patients initially think. Consider honestly:

If you strongly prefer pills: Oral Wegovy (available now, $199-299/month cash) or orforglipron (pending approval, $149/month). Oral Wegovy requires empty-stomach dosing; orforglipron does not.
If injections are acceptable: You have access to the most effective current medications — Zepbound (20.9% weight loss) and Wegovy (14.9%).
If you are injection-averse but want maximum efficacy: Oral Wegovy delivers 16.6% weight loss, which is competitive with injectable Wegovy. It is worth trying before ruling out GLP-1s due to needle aversion.

Step 3: How Much Weight Loss Do You Need?

Weight loss goals should be discussed with your prescriber, but as a general framework:

10-15% weight loss goal: Any approved GLP-1 is likely sufficient. Even orforglipron's 11.2% (if approved) meets this threshold for most patients.
15-20% weight loss goal: Zepbound (20.9%) or oral Wegovy (16.6%) are the strongest current options.
20%+ weight loss goal: Zepbound is the only currently available medication with mean weight loss above 20%. CagriSema (23%) and retatrutide (28.7%) could eventually serve this tier but are not yet available.

Step 4: What Can You Afford?

Budget	Best Option
$25-50/month (with insurance)	Wegovy or Zepbound through insurance
$50/month (Medicare)	Wegovy or Zepbound through Medicare
$99-199/month (cash)	Compounded semaglutide
$149/month (cash, pending approval)	Orforglipron
$199-299/month (cash)	Oral Wegovy or compounded tirzepatide
$935-1,349/month (cash, no discounts)	Brand-name Ozempic, Wegovy, Zepbound

By Patient Situation

Best Overall Efficacy (Available Now)

Tirzepatide (Zepbound) — 20.9% mean body weight loss in the SURMOUNT-1 trial. This is the most effective FDA-approved weight loss medication as of April 2026. It works through dual GIP/GLP-1 receptor agonism, hitting two incretin pathways instead of one.

Best Oral Option (Available Now)

Oral Wegovy (semaglutide) — 16.6% mean body weight loss in a once-daily pill. The trade-off: you must take it on an empty stomach 30 minutes before eating or drinking, and nausea rates are slightly higher than the injectable version (47% vs. 44%). For patients who refuse injections, this is currently the most effective oral choice.

Most Affordable Without Insurance

Compounded semaglutide — $99-199/month from reputable compounding pharmacies. Not FDA-approved as a finished product, and quality varies by pharmacy. But for patients paying entirely out of pocket, the price difference is substantial. If orforglipron is approved, it will compete in this tier at $149/month with the advantage of being FDA-approved and in pill form.

Best With Commercial Insurance

Wegovy or Zepbound — depending on your plan's formulary. With manufacturer savings cards and insurance coverage, copays typically run $25-50/month. Check your specific plan: some cover one but not the other, and some require prior authorization or step therapy.

Best for Medicare Beneficiaries

Wegovy or Zepbound — Medicare is expected to cover both for weight management at a capped $50/month out-of-pocket cost via the Bridge program (scheduled July 2026). This will represent a major change from prior policy, when Medicare explicitly excluded weight loss medications. If you are on Medicare, check your Part D plan and watch for the July 2026 Bridge program launch.

Coming Soon: Best Convenience + Affordability

Orforglipron (PDUFA April 10, 2026) — a once-daily oral GLP-1 with no food-timing restrictions at $149/month. Lower efficacy than injectables (11.2% weight loss), but the combination of oral convenience, no fasting requirements, and aggressive pricing fills a gap that no current medication addresses. If the FDA approves it on schedule, orforglipron could be available by mid-2026.

Highest Future Efficacy

Retatrutide — 28.7% mean body weight loss in Phase 3 (TRIUMPH-1), the highest ever recorded in a rigorous obesity trial. A triple agonist targeting GLP-1, GIP, and glucagon receptors. Not yet available; estimated approval in 2027-2028. This is the drug to watch for patients who want maximum possible weight loss, but it requires patience.

Efficacy Comparison

To put the weight loss numbers in context, here is how each medication ranks by mean percentage body weight loss from clinical trials.

Rank	Drug	Weight Loss	Status	Notes
1	Retatrutide	28.7%	Phase 3	Triple agonist; not yet available
2	CagriSema	23%	NDA filed	GLP-1/amylin combo; 2026 decision
3	Amycretin	22%	Phase 3	Phase 1b/2 data; preliminary
4	Tirzepatide (Zepbound)	20.9%	FDA-approved	Best available now
5	Survodutide	18.7%	Phase 3	Phase 2 data; preliminary
6	Oral Wegovy	16.6%	FDA-approved	Best oral option now
7	Aleniglipron	16.3%	Phase 2	Preliminary; Phase 3 starting 2026
8	Wegovy (injection)	14.9%	FDA-approved	Established, extensive data
9	Ozempic	~12%	FDA-approved	Diabetes indication; off-label for weight
10	Orforglipron	11.2%	FDA review	Phase 3 confirmed; decision Apr 2026

Important context: These numbers are not directly comparable across drugs. Trial designs differ in duration, patient populations, dosing protocols, and endpoints. A drug with 20.9% weight loss in one trial is not necessarily "twice as effective" as one with 11.2% in a different trial. Head-to-head trials are the gold standard for comparison, and very few exist between these medications.

The most reliable comparison is between semaglutide and tirzepatide, where the SURMOUNT and STEP trials used similar designs and populations. For pipeline drugs, take the numbers as directional rather than definitive.

Side Effects Compared

All GLP-1-class medications share a common side effect profile rooted in their mechanism of action. The GI effects — nausea, vomiting, diarrhea, constipation — are the most frequent and the most commonly cited reason for discontinuation.

Drug	Nausea	Vomiting	Diarrhea	Constipation	Discontinuation (side effects)
Wegovy (injection)	44%	24%	30%	24%	~7%
Oral Wegovy	47%	26%	21%	18%	~8%
Zepbound/Mounjaro	31%	12%	23%	13%	~5%
Ozempic (2 mg)	20%	8%	11%	6%	~4%
Orforglipron	~33%	~14%	~20%	~11%	~6%
CagriSema	~45%	~20%	~25%	~20%	~7%
Retatrutide	~46%	~22%	~34%	~16%	~6%

How to read this table:

Nausea rates are from the titration and maintenance phases combined. Most nausea occurs during dose escalation and improves over time.
Tirzepatide (Zepbound/Mounjaro) has consistently lower GI side effect rates than semaglutide in clinical trials, despite producing more weight loss. This is one of its clearest advantages.
Pipeline drug side effect data comes from trials with smaller sample sizes and may shift as Phase 3 data matures.
Ozempic's lower side effect rates partly reflect its lower dosing (2 mg max vs. Wegovy's 2.4 mg) and its diabetes trial population.

Serious but Rare Side Effects

All GLP-1 medications carry warnings for pancreatitis, gallbladder events, and thyroid C-cell tumors (based on animal studies). These are rare in clinical trials and post-market surveillance, but they are real considerations:

Pancreatitis: Reported in <1% of patients across GLP-1 trials. Patients with a history of pancreatitis should discuss risk with their prescriber.
Gallbladder events: Gallstones and cholecystitis occur at higher rates with rapid weight loss of any kind, not just GLP-1 therapy. Rates are slightly elevated in GLP-1 trials.
Thyroid tumors: A boxed warning on all GLP-1 medications based on rodent studies. No causal link has been established in humans, but GLP-1s are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Pricing Compared

GLP-1 pricing is notoriously confusing. The "list price" that manufacturers publish bears little relationship to what most patients actually pay. Here is a breakdown of what each medication actually costs under different scenarios.

Drug	List Price	With Insurance	With Savings Card	Medicare	Cash (No Insurance)
Wegovy (injection)	$1,349/mo	$25-50/mo copay	$0-25/mo (if eligible)	$50/mo cap	$1,349/mo
Oral Wegovy	$199-299/mo	$25-50/mo copay	$0-25/mo (if eligible)	$50/mo cap	$199-299/mo
Ozempic	$935/mo	$25-50/mo copay	$25/mo (savings card)	$35/mo cap	$935/mo
Zepbound	$1,060/mo	$25-50/mo copay	$0-25/mo (if eligible)	$50/mo cap	$550/mo (LillyDirect)
Mounjaro	$1,060/mo	$25-50/mo copay	$25/mo (savings card)	$35/mo cap	$1,060/mo
Orforglipron (est.)	$149/mo	TBD	TBD	TBD	$149/mo
Compounded semaglutide	N/A	Not covered	N/A	Not covered	$99-199/mo
Compounded tirzepatide	N/A	Not covered	N/A	Not covered	$249-349/mo

Key pricing notes:

Zepbound through LillyDirect: Eli Lilly's direct-to-consumer program sells Zepbound at $550/month for cash-pay patients — significantly below list price. This is currently the lowest branded injectable price for patients without insurance.
Manufacturer savings cards are available for most branded GLP-1s but typically exclude government insurance (Medicare, Medicaid, Tricare). Eligibility requirements vary.
Orforglipron's $149/month is Eli Lilly's announced price through LillyDirect, pending FDA approval. Insurance coverage and copay structures are not yet determined.
Oral Wegovy was priced significantly below injectable Wegovy at launch — a deliberate strategy by Novo Nordisk to compete with orforglipron on price.
Prices shown are as of April 2026 and may change. Check manufacturer websites and your pharmacy for current pricing.

Insurance Coverage Compared

Insurance coverage for GLP-1 medications has improved substantially since 2024, but it remains inconsistent across plans and payers. Here is the current landscape.

Commercial Insurance

Drug	Typical Coverage	Common Restrictions
Wegovy	Covered by ~65% of commercial plans	Prior auth; BMI >=30 or >=27 with comorbidity
Oral Wegovy	Covered by ~60% of commercial plans	Prior auth; same BMI requirements
Zepbound	Covered by ~60% of commercial plans	Prior auth; some plans require Wegovy failure first
Ozempic	Covered by ~90% of commercial plans	Diabetes diagnosis required
Mounjaro	Covered by ~85% of commercial plans	Diabetes diagnosis required

Medicare

Following the expansion of Medicare coverage for anti-obesity medications under the Treat and Reduce Obesity Act provisions and Inflation Reduction Act implementation:

Wegovy and Zepbound are now covered under Medicare Part D for weight management
Monthly out-of-pocket cap of $50/month under the Inflation Reduction Act
Prior authorization is required — BMI >= 30 or >= 27 with at least one weight-related comorbidity
Coverage began in 2026 for weight management indications

Medicaid

Coverage varies significantly by state. As of April 2026, approximately 30 states provide some level of Medicaid coverage for FDA-approved weight loss medications, though formularies, prior authorization requirements, and preferred agents differ.

What to Do If Coverage Is Denied

Request the specific denial reason in writing from your insurer.
File a formal appeal — many initial denials are overturned on appeal, particularly with documentation of BMI, comorbidities, and prior weight loss attempts.
Ask your prescriber for a peer-to-peer review with the insurance company's medical director.
Check manufacturer patient assistance programs — Novo Nordisk and Eli Lilly both offer programs for patients who cannot afford their medications.
Consider compounded alternatives as a bridge while appealing.

For a detailed guide to the appeals process, see our insurance stopped covering GLP-1 guide.

Frequently Asked Questions

What is the best GLP-1 medication overall?

There is no single best medication — it depends on your situation. If you have insurance and can tolerate injections, Zepbound offers the highest efficacy among approved drugs (20.9% weight loss). If you prefer pills, Oral Wegovy is the most effective oral option (16.6%). If cost is the deciding factor and you have no insurance, compounded semaglutide ($99-199/month) or the soon-to-be-available orforglipron ($149/month) offer the most affordable paths to treatment.

Is tirzepatide (Zepbound) better than semaglutide (Wegovy)?

By weight loss numbers alone, yes — tirzepatide produces more weight loss (20.9% vs. 14.9%) with fewer GI side effects in clinical trials. However, semaglutide has a longer track record, more published safety data, cardiovascular outcomes trial results (SELECT trial), and wider insurance coverage. Both are effective medications. The choice often comes down to insurance formulary, prescriber preference, and individual response.

Should I wait for orforglipron instead of starting something now?

If the FDA decision is weeks away (PDUFA April 10, 2026) and you specifically want an affordable oral option, a short wait may be reasonable. But do not delay treatment indefinitely for a drug that has not yet been approved. Obesity is a progressive condition, and effective medications are available today. You can always switch later if orforglipron is approved and better fits your needs.

How do compounded GLP-1s compare to brand-name versions?

Compounded versions use the same active ingredient but are prepared by compounding pharmacies, not the original manufacturer. They have not undergone the same FDA approval process for the finished product. Potency, sterility, and consistency can vary by pharmacy. The primary advantage is cost ($99-199/month vs. $935-1,349/month for brand names). If you use compounded medications, choose a 503B-registered outsourcing facility for the highest quality standards.

Can I switch between GLP-1 medications?

Yes, switching is common and generally straightforward. Patients frequently switch from semaglutide to tirzepatide (or vice versa) based on response, side effects, insurance changes, or availability. Your prescriber will typically start you at a lower dose of the new medication and titrate up, similar to starting from scratch, to minimize side effects during the transition.

What about generic GLP-1 medications?

No generic versions of semaglutide or tirzepatide are available as of April 2026. Patent protections for Wegovy and Zepbound extend into the early 2030s. Compounded versions exist but are not the same as FDA-approved generics. For our analysis of when generics may become available, see our generic Wegovy availability guide.

Are GLP-1 medications safe long-term?

Semaglutide has the longest safety record in the class, with the SELECT cardiovascular outcomes trial demonstrating a 20% reduction in major cardiovascular events over a median of 40 months. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. The GLP-1 class has been used clinically for type 2 diabetes since 2005 (exenatide), providing nearly two decades of post-market safety data for the drug class as a whole. Serious adverse events are rare but include pancreatitis, gallbladder events, and the theoretical thyroid tumor risk discussed above.

Will any of these pipeline drugs replace current medications?

Not immediately. New drugs enter the market alongside existing ones, giving patients more options rather than replacing what works. Over time, if drugs like retatrutide (28.7% weight loss) prove safe and effective in the real world, they may become preferred first-line treatments. But semaglutide and tirzepatide will remain available and appropriate for many patients even after newer drugs launch.

How often is this page updated?

We update this comparison chart whenever a new drug is approved, pricing changes materially, new clinical trial data is published, or insurance coverage shifts significantly. Check the "last updated" date at the top of the page. For the latest developments on individual medications, see our linked drug-specific guides throughout this page.

This guide is for informational purposes only and does not constitute medical advice. Clinical trial data cited represents mean results from published studies; individual outcomes vary. Pipeline medications are investigational and not yet FDA-approved. Pricing information is current as of April 2026 and subject to change. Insurance coverage varies by plan, state, and individual circumstances. Consult with a qualified healthcare provider before starting, stopping, or switching any medication. Last updated April 2026.

Related Comparisons

Amazon Clinic vs Ro Health for GLP-1 Weight Loss: Big Tech vs Dedicated Program

Amazon Clinic vs Ro Health for GLP-1: retail giant pharmacy access vs dedicated weight loss program. Pricing, clinical depth, and medication access compared. April 2026.

Eden Health vs Ro for GLP-1: 2026 Comparison

Eden Health vs Ro compared side-by-side — flat-rate compounded pricing vs brand-name medications, and which GLP-1 provider fits your situation in 2026.

eMed vs Ro for GLP-1 Weight Loss: 2026 Comparison

eMed vs Ro compared side-by-side — smart scale, video consultations, and adherence tech vs Ro's streamlined brand-name GLP-1 approach. Pricing, clinical model, and who each fits.

GLP-1 Medication Comparison Chart 2026: Every Weight Loss Drug Compared

Key Takeaways

GLP-1 Medication Comparison Chart 2026: Every Weight Loss Drug Compared

Master Comparison Chart: FDA-Approved Medications

Key Takeaways from the Approved Drug Chart

Pipeline Medications: Not Yet Available

Compounded Options

How to Choose: Decision Framework

Step 1: What Can You Access?

Step 2: Pills or Injections?

Step 3: How Much Weight Loss Do You Need?

Step 4: What Can You Afford?

By Patient Situation

Best Overall Efficacy (Available Now)

Best Oral Option (Available Now)

Most Affordable Without Insurance

Best With Commercial Insurance

Best for Medicare Beneficiaries

Coming Soon: Best Convenience + Affordability

Highest Future Efficacy

Efficacy Comparison

Side Effects Compared

Serious but Rare Side Effects

Pricing Compared

Insurance Coverage Compared

Commercial Insurance

Medicare

Medicaid

What to Do If Coverage Is Denied

Frequently Asked Questions

What is the best GLP-1 medication overall?

Is tirzepatide (Zepbound) better than semaglutide (Wegovy)?

Should I wait for orforglipron instead of starting something now?

How do compounded GLP-1s compare to brand-name versions?

Can I switch between GLP-1 medications?

What about generic GLP-1 medications?

Are GLP-1 medications safe long-term?

Will any of these pipeline drugs replace current medications?

How often is this page updated?

Related Comparisons

Amazon Clinic vs Ro Health for GLP-1 Weight Loss: Big Tech vs Dedicated Program

Eden Health vs Ro for GLP-1: 2026 Comparison

eMed vs Ro for GLP-1 Weight Loss: 2026 Comparison

More Guides

Does Aetna Cover GLP-1 Medications? 2026 Coverage Guide

Aleniglipron: Structure Therapeutics' Oral GLP-1 — What Patients Need to Know

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

AOD-9604 for Weight Loss: Telehealth Providers Guide 2026

Best GLP-1 Medication 2026: Every Approved Option Ranked by Use Case

Which GLP-1 Has the Fewest Side Effects? A Medication-by-Medication Comparison

Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026

Best GLP-1 Pill Options in 2026: Oral Wegovy, Orforglipron & More

Best Oral GLP-1 Options 2026: Foundayo vs Rybelsus Complete Comparison

Best GLP-1 Under $200 Per Month: 2026 Budget Guide

Best GLP-1 Weight Loss Programs 2026: Every Major Provider Ranked

Best Growth Hormone Peptide Providers Online: 2026 Independent Comparison

Best Online HRT 2026: Telehealth Menopause Treatment Platforms Compared

Best Online TRT Clinics 2026: Telehealth Testosterone Replacement Compared

Best Oral GLP-1 Options in 2026: Every Pill Compared

Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care

Best Weight Loss Injection 2026: Wegovy HD, Zepbound, and Every Option Compared

Best Weight Loss Medication 2026: Every FDA-Approved Option Ranked

Does Blue Cross Blue Shield Cover GLP-1 Medications? 2026 Guide

Best BPC-157 Telehealth Providers 2026: Complete Guide

BPC-157 vs TB-500: Which Injury Recovery Peptide Is Right for You?

CagriSema Dosing Guide: Titration Schedule, Dose Steps & What to Expect

CagriSema Launch Day Patient Guide: What to Do Now That It's Here

CagriSema: The Semaglutide + Cagrilintide Combination — Patient Guide

CagriSema FDA Decision Guide: What to Expect and How to Prepare

CagriSema: What Patients Need to Know While the FDA Decision Drags On

CagriSema Side Effects: What Clinical Trials Show About Safety and Tolerability

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

CJC-1295 vs Ipamorelin: Complete Telehealth Comparison Guide 2026

CMS BALANCE Model Explained: Medicaid Obesity Care for 2026 and Beyond

Medicare GLP-1 Bridge Program: Implementation FAQ for Patients

Compounded GLP-1 Shutdown Timeline: From Shortage to Enforcement (2023–2026)

Is Compounded HRT Safe? What Patients Need to Know in 2026

Is Compounded Semaglutide Legal and Safe in 2026?

Compounded Tirzepatide 2026: What's Happening and What Patients Should Do